{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T02:10:48Z","timestamp":1787019048578,"version":"build-2736575974"},"reference-count":29,"publisher":"SAGE Publications","issue":"5","license":[{"start":{"date-parts":[[2024,10,7]],"date-time":"2024-10-07T00:00:00Z","timestamp":1728259200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Ann Pharmacother"],"published-print":{"date-parts":[[2025,5]]},"abstract":"<jats:sec>\n                    <jats:title>Objective:<\/jats:title>\n                    <jats:p>To review the pharmacology, efficacy, safety, dosing and administration, and relevance to patient care and clinical practice of B-cell maturation antigen (BCMA) directed immunotherapies, including chimeric antigen receptor T-cell (CAR-T) therapy and bispecific antibodies (BsAb), for the management of relapsed\/refractory multiple myeloma (RRMM).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Data Sources:<\/jats:title>\n                    <jats:p>\n                      A literature review of PubMed (1966 to July 2024) was conducted using the keywords\n                      <jats:italic>idecabtagene vicleucel<\/jats:italic>\n                      ,\n                      <jats:italic>ciltacabtagene autoleucel, teclistamab, elranatamab<\/jats:italic>\n                      , and\n                      <jats:italic>multiple myeloma<\/jats:italic>\n                      . Data was also obtained from unpublished meeting abstracts and prescribing information.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Study Selection and Data Extraction:<\/jats:title>\n                    <jats:p>All relevant published articles, unpublished abstracts, and prescribing information on anti-BCMA immunotherapies for the treatment of RRMM were reviewed.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Data Synthesis:<\/jats:title>\n                    <jats:p>Idecabtagene vicleucel and ciltacabtagene autoleucel are BCMA-directed CAR-T cell therapies that have been compared to standard of care (SOC) regimens for MM in early relapse in the phase III trials KarMMa-3 and CARTITUDE-4, respectively. Both studies demonstrated a significantly improved in response rates, depth of response, and progression-free survival compared to SOC. BsAbs teclistamab and elranatamab have been evaluated in the phase II trials MajesTEC-1 and MagnetisMM-3, respectively. Overall response rates of 63 and 61% were observed with teclistamab and elranatamab, respectively, in a population of patients with heavily pretreated RRMM.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Relevance to Patient Care and Clinical Practice in Comparison with Existing Drugs:<\/jats:title>\n                    <jats:p>BCMA-directed immunotherapies have demonstrated efficacy in the treatment of RRMM. Safety issues with BCMA-directed immunotherapies include cytokine release syndrome, neurotoxicity, infections, and cytopenias. Operational challenges and issues with access to care exist with these therapies as they may be limited to institutions with the infrastructure to safely administer and monitor patients for toxicities.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion:<\/jats:title>\n                    <jats:p>BCMA-directed immunotherapies represent an important advancement in the management of RRMM and have significantly added to the available treatment options for this disease.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/10600280241282115","type":"journal-article","created":{"date-parts":[[2024,10,8]],"date-time":"2024-10-08T08:37:34Z","timestamp":1728376654000},"page":"463-472","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":3,"title":["B-Cell Maturation Antigen-Directed Immunotherapies for the Treatment of Relapsed\/Refractory Multiple Myeloma: A Review of the Literature and Implications for Clinical Practice"],"prefix":"10.1177","volume":"59","author":[{"given":"Matthew R.","family":"Peery","sequence":"first","affiliation":[{"name":"Department of Pharmacy, Virginia Commonwealth University Medical Center, VCU Health, Richmond, VA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hailey","family":"Hill","sequence":"additional","affiliation":[{"name":"Division of Pharmacy, Atrium Health Levine Cancer Institute, Atrium Health, Charlotte, NC, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amanda","family":"Sharps","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Virginia Commonwealth University Medical Center, VCU Health, Richmond, VA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aarti","family":"Zaver","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Virginia Commonwealth University Medical Center, VCU Health, Richmond, VA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5629-9505","authenticated-orcid":false,"given":"Donald C.","family":"Moore","sequence":"additional","affiliation":[{"name":"Division of Pharmacy, Atrium Health Levine Cancer Institute, Atrium Health, Charlotte, NC, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2024,10,7]]},"reference":[{"key":"e_1_3_2_2_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-020-0311-8"},{"key":"e_1_3_2_3_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(21)00466-6"},{"key":"e_1_3_2_4_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2312054"},{"key":"e_1_3_2_5_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-021-01471-3"},{"key":"e_1_3_2_6_2","volume-title":"Abecma (Idecabtagene Vicleucel)","author":"Celgene Corporation","year":"2024","unstructured":"Celgene Corporation. Abecma (Idecabtagene Vicleucel). [prescribing information]. Celgene Corporation; 2024."},{"key":"e_1_3_2_7_2","volume-title":"Carvykti (Ciltacabtagene Autoleucel)","author":"Janssen Biotech Inc","year":"2024","unstructured":"Janssen Biotech Inc. Carvykti (Ciltacabtagene Autoleucel). [prescribing information]. Janssen Biotech Inc; 2024."},{"key":"e_1_3_2_8_2","volume-title":"Tecvayli (Teclistamab)","author":"Janssen Biotech Inc","year":"2024","unstructured":"Janssen Biotech Inc. Tecvayli (Teclistamab). [prescribing information]. Janssen Biotech Inc; 2024."},{"key":"e_1_3_2_9_2","volume-title":"Elrexfio (Elranatamab)","author":"Pfizer Inc","year":"2023","unstructured":"Pfizer Inc. Elrexfio (Elranatamab). [prescribing information]. Pfizer Inc; 2023."},{"key":"e_1_3_2_10_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2003-06-2043"},{"key":"e_1_3_2_11_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2016-01-691162"},{"key":"e_1_3_2_12_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2012.09241.x"},{"key":"e_1_3_2_13_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2024850"},{"key":"e_1_3_2_14_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2213614"},{"key":"e_1_3_2_15_2","unstructured":"NCCN clinical practice guidelines in oncology (NCCN guidelines\u00ae) for multiple myeloma. V4. 2024. https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/myeloma.pdf"},{"key":"e_1_3_2_16_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(21)00933-8"},{"key":"e_1_3_2_17_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2303379"},{"key":"e_1_3_2_18_2","unstructured":"NCCN clinical practice guidelines in oncology (NCCN guidelines\u00ae) for prevention and treatment of cancer-related infections. V1. 2024. https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/infections.pdf"},{"key":"e_1_3_2_19_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2203478"},{"key":"e_1_3_2_20_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2023.41.16_suppl.8034"},{"key":"e_1_3_2_21_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-023-02528-9"},{"key":"e_1_3_2_22_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2018.12.758"},{"key":"e_1_3_2_23_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2023.41.16_suppl.8011"},{"key":"e_1_3_2_24_2","unstructured":"U.S. Food and Drug Administration. FDA Requires boxed warning for T cell malignancies following treatment with BCMA-directed or CD19-directed autologous chimeric antigen receptor (CAR) T cell immunotherapies. Accessed April 10 2024. https:\/\/www.fda.gov\/vaccines-blood-biologics\/safety-availability-biologics\/fda-requires-boxed-warning-t-cell-malignancies-following-treatment-bcma-directed-or-cd19-directed"},{"key":"e_1_3_2_25_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMp2400209"},{"key":"e_1_3_2_26_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2023-174270"},{"key":"e_1_3_2_27_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2023-187186"},{"key":"e_1_3_2_28_2","doi-asserted-by":"publisher","DOI":"10.1007\/s40259-022-00557-3"},{"key":"e_1_3_2_29_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtct.2023.10.001"},{"key":"e_1_3_2_30_2","doi-asserted-by":"publisher","DOI":"10.1007\/s12325-023-02623-w"}],"container-title":["Annals of Pharmacotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/10600280241282115","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/10600280241282115","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/10600280241282115","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T11:13:51Z","timestamp":1777374831000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/10600280241282115"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10,7]]},"references-count":29,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2025,5]]}},"alternative-id":["10.1177\/10600280241282115"],"URL":"https:\/\/doi.org\/10.1177\/10600280241282115","relation":{},"ISSN":["1060-0280","1542-6270"],"issn-type":[{"value":"1060-0280","type":"print"},{"value":"1542-6270","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,10,7]]}}}